164 related articles for article (PubMed ID: 19606930)
1. The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer.
Puré E
Expert Opin Ther Targets; 2009 Aug; 13(8):967-73. PubMed ID: 19606930
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy.
Kelly T
Drug Resist Updat; 2005; 8(1-2):51-8. PubMed ID: 15939342
[TBL] [Abstract][Full Text] [Related]
3. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
4. Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.
Meadows SA; Edosada CY; Mayeda M; Tran T; Quan C; Raab H; Wiesmann C; Wolf BB
Biochemistry; 2007 Apr; 46(15):4598-605. PubMed ID: 17381073
[TBL] [Abstract][Full Text] [Related]
5. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review).
Zi F; He J; He D; Li Y; Yang L; Cai Z
Mol Med Rep; 2015 May; 11(5):3203-11. PubMed ID: 25593080
[TBL] [Abstract][Full Text] [Related]
7. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
Cheng JD; Dunbrack RL; Valianou M; Rogatko A; Alpaugh RK; Weiner LM
Cancer Res; 2002 Aug; 62(16):4767-72. PubMed ID: 12183436
[TBL] [Abstract][Full Text] [Related]
8. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
[TBL] [Abstract][Full Text] [Related]
9. Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.
Christiansen VJ; Jackson KW; Lee KN; Downs TD; McKee PA
Neoplasia; 2013 Apr; 15(4):348-58. PubMed ID: 23555181
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of fibroblast activation protein in patients with colon cancer.
Henry LR; Lee HO; Lee JS; Klein-Szanto A; Watts P; Ross EA; Chen WT; Cheng JD
Clin Cancer Res; 2007 Mar; 13(6):1736-41. PubMed ID: 17363526
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells.
Lai D; Ma L; Wang F
Int J Oncol; 2012 Aug; 41(2):541-50. PubMed ID: 22614695
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro.
Teichgräber V; Monasterio C; Chaitanya K; Boger R; Gordon K; Dieterle T; Jäger D; Bauer S
Adv Med Sci; 2015 Sep; 60(2):264-72. PubMed ID: 26057860
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast activation protein: A potential therapeutic target in cancer.
Liu R; Li H; Liu L; Yu J; Ren X
Cancer Biol Ther; 2012 Feb; 13(3):123-9. PubMed ID: 22236832
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?
Juillerat-Jeanneret L; Tafelmeyer P; Golshayan D
Expert Opin Ther Targets; 2017 Oct; 21(10):977-991. PubMed ID: 28829211
[TBL] [Abstract][Full Text] [Related]
16. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
Ostermann E; Garin-Chesa P; Heider KH; Kalat M; Lamche H; Puri C; Kerjaschki D; Rettig WJ; Adolf GR
Clin Cancer Res; 2008 Jul; 14(14):4584-92. PubMed ID: 18628473
[TBL] [Abstract][Full Text] [Related]
17. FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor.
Ramirez-Montagut T; Blachere NE; Sviderskaya EV; Bennett DC; Rettig WJ; Garin-Chesa P; Houghton AN
Oncogene; 2004 Jul; 23(32):5435-46. PubMed ID: 15133496
[TBL] [Abstract][Full Text] [Related]
18. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy.
Hamson EJ; Keane FM; Tholen S; Schilling O; Gorrell MD
Proteomics Clin Appl; 2014 Jun; 8(5-6):454-63. PubMed ID: 24470260
[TBL] [Abstract][Full Text] [Related]
19. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity.
Edosada CY; Quan C; Tran T; Pham V; Wiesmann C; Fairbrother W; Wolf BB
FEBS Lett; 2006 Mar; 580(6):1581-6. PubMed ID: 16480718
[TBL] [Abstract][Full Text] [Related]
20. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
